2026年10月1日-16日，全球医药市场共签署了66项资产授权和合作协议。中国市场共达成17项交易，包括11项出海交易、2项引进交易和4项国内交易。
中国市场，本周最大的出海交易是艾博生物与Novartis签署许可及期权协议，包括ABO2203的全球独家许可权，以及多个下一代潜在项目的独家选择权，首付款5.75亿美元，总金额可达78亿美元。
中国以外市场，本周共签署了49项资产授权和合作协议。最大的交易是Regeneron与Sanofi达成战略研究合作，共同开发和商业化多款下一代长效免疫抗体，首付款10亿美元，潜在里程碑达70亿美元。
From October 1 to 16, a total of 66 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 17 were China-related, defined as transactions involving at least one China-based company. These comprised eleven out-licensing deals, two in-licensing deals, and four domestic partnerships.
In China, the largest transaction involved Abogen Biosciences and Novartis, including an exclusive worldwide license to ABO2203, and exclusive options to license other potential next-generation programs, with an upfront payment of $575 million and a total deal value of $7.8 billion.
Outside China, 49 deals were announced. The largest transaction involved Regeneron and Sanofi for multiple next-generation, long-acting immunology antibodies, with an upfront payment of $1 billion and potential milestone payments of up to $8 billion.
3. M&A Deals
4. Top Deals of 2026
